The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention

Thrombosis and Haemostasis

Volumn 106, Issue 1, 2011, Pages 165-171

  van Loon, Janine E ^a   de Jaegere, Peter P T ^a   Ulrichts, Hans ^b   van Vliet, Huub H D M ^a   de Maat, Moniek P M ^a   de Groot, Philip G ^c   Simoons, Maarten L ^a   Leebeek, Frank W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ALX 0081; Antithrombotic drugs; PTCA; Von willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ALX 0081; ANTICOAGULANT AGENT; CLOPIDOGREL; HEPARIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ANALYZER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADMINISTRATION, CUTANEOUS; ANGIOPLASTY; ANIMALS; ANTIBODIES, BISPECIFIC; CORONARY ARTERY DISEASE; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; HUMANS; MICE; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; POSTOPERATIVE COMPLICATIONS; PROTEIN BINDING; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 79960071636     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-12-0804     Document Type: Article

References (34)

1. Silber S, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-847.
2. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
3. Therapy EIESotPIIRwI. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356: 2037-2044.
4. Spiel AO, et al. Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117: 1449-1459.
5. Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000; 105: 699-701.
6. Ruggeri ZM, Ware J. von Willebrand factor. Faseb J 1993; 7: 308-316.
7. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255-265.
8. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005; 42: 49-55.
9. Fuchs I, et al. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006; 4: 2547-2552.
10. Wiman B, et al. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 2019-2023.
11. Holz J. ALX-0081 a novel anti-platelet thrombotic: first results of a multiple dose phase I study in patients with stable angina undergoing PCI. J Thromb Haemost 2009; 7(Suppl. 2): 765.
12. Ulrichts H. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs (abstract). Blood 2011; epub.
13. Deckmyn H, et al. Development of antibodies that interfere with the collagen- VWF-GPIb axis as new antithrombotics. Verh K Acad Geneeskd Belg 2005; 67: 55-65.
14. De Vleeschauwer A, Devreese K. Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease. Blood Coagul Fibrinolysis 2006; 17: 353-358.
15. Sucker C, et al. Determination of von Willebrand factor activity: evaluation of the HaemosIL assay in comparison with established procedures. Clin Appl Thromb Hemost 2006; 12: 305-310.
16. Sakariassen KS, et al. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983; 102: 522-535.
17. Dong JF, et al. Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood 2001; 97: 162-168.
18. Mammen EF, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
19. Mega JL, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
20. Simon T, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
21. Gurbel PA, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
22. Jaremo P, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-238.
23. Firbas C, et al. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 2010; 8: 1689-1701.
24. Gilbert JC, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116: 2678-2686.
25. Spiel AO, et al. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 2009; 20: 334-340.
26. Jilma B, et al. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost 2010; 104: 563-570.
27. Jilma-Stohlawetz P, et al. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105: 545-552.
28. Lisman T, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-1870.
29. Lisman T, et al. Recombinant factor VIIa restores aggregation of alphaIIbbeta3- deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-1727.
30. Frossard M, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397.
31. Campo G, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006; 48: 2178-2185.
32. Van der Planken MG, et al. Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thromb Res 2003; 111: 159-164.
33. Peters AJ, et al. In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. J Thromb Thrombolysis 2001; 12: 263-272.
34. Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia 2001; 7: 170-179.